In general, in patients with high expression of AP components, targeting these molecules, especially targeting the entire AP, can alter the immunosuppressive GME to the immune-active environment and have outstanding effects in controlling GBM [59,60] (Table 2). The gene discussed is DHCR7-DT; the disease is glioblastoma.